Introduction

ADHD medications are prescription treatments used to reduce the core symptoms of attention-deficit/hyperactivity disorder—inattention, hyperactivity, and impulsivity—so that day-to-day functioning (school, work, relationships, driving, organisation) is easier. They don’t “cure” ADHD, but for many people they meaningfully improve focus, self-control, and emotional regulation when used as part of a broader plan (skills, routines, coaching/therapy, school/work adjustments).

Most ADHD medicines work by changing levels of dopamine and/or noradrenaline (norepinephrine) in brain circuits involved in attention and executive function. Typically these medications come under the category of stimulants, such as Methylphenidate and Amphetamines. Despite the name, “stimulant” doesn’t mean they make everyone feel wired; in ADHD they often improve calm focus. Stimulants are widely used because they tend to work quickly and have a strong evidence base.

How do they work?

Stimulants work by increasing the signalling certain neurotransmitters in the brain. Neurotransmitters are essentially chemical transmitters that transmit signals between neurons. In particular, stimulants work by increasing the signalling of dopamine and norepinephrine.

Low doses of methylphenidate/amphetamines enhance attention and executive function in both ADHD and non-ADHD subjects. Berridge and colleagues’ key finding is that clinically relevant low doses preferentially boost dopamine and norepinephrine in the prefrontal cortex (PFC), while causing only small changes in deeper subcortical regions.

Because the PFC supports working memory and top-down control and tends to function less effectively in ADHD, this targeted catecholamine increase helps explain why stimulants improve symptoms.

Mechanism of Action

Whilst both methylphenidate and amphetamine raise dopamine (DA) and norepinephrine (NE) signalling in key brain circuits. The key difference is how they do it:

Methylphenidate: reuptake blocker

• Primary action: inhibits the dopamine transporter (DAT) and norepinephrine transporter (NET).
• What that means: DA and NE that are released into the synapse aren’t taken back up as quickly, so their extracellular levels rise.

Amphetamine: releasing agent + reuptake blocking

• Primary action: acts more like a substrate for DAT/NET (it gets transported into the presynaptic neuron), and then promotes release of DA/NE.
• Key steps described in pharmacology sources:
  • Enters the nerve terminal via DAT/NET.
  • Increases cytosolic monoamines partly by acting on VMAT2 (shifts monoamines out of vesicles), and then drives reverse transport through DAT/NET so DA/NE are pushed out into the synapse.

The key difference between these molecules is that amphetamine has an additional action on VMAT2 (Vesicular Monoamine Transporter 2). Because the amphetamine molecule is similar enough to natural neurotransmitters, it gets carried into cell. Here it interferes with VMAT2, which normally packages up dopamine and noradrenaline into storage pockets called vesicles. Amphetamine allows for the release of these stored up neurotransmitters from the vesicles.

Methylphenidate doesn’t share this molecular similarity to natural neurotransmitters, and so isn’t carried into the cell. It has a much simpler mechanism of action by simply blocking the reuptake. Since amphetamine is a dopamine releasing agent, it much more strongly raises extracellular dopamine (even accounting for dosing). A study on rodents found that methylphenidate (5 mg/kg) raised striatal extracellular DA by ~360%, whilst AMP (2.5 mg/kg) raised it by ~1400% (Schiffer et al., 2006).

Neurotoxic Mechanisms

Excessive DA/NE stimulation from stimulants can harm the brain through several different pathways. The strongest evidence for true neurotoxic injury is for amphetamine-class drugs at high exposures (particularly methamphetamine), while therapeutic ADHD dosing is a different situation and is not generally considered neurotoxic.

1) Oxidative stress from dopamine overload

• When dopamine in the cytosol rises excessively (a hallmark of amphetamine “releasing” action), it’s more likely to undergo enzymatic and non-enzymatic oxidation, generating reactive oxygen/nitrogen species (ROS/RNS) and reactive dopamine metabolites/quinones that can damage proteins, lipids, and DNA.

2) Excitoxicity via glutamate “spillover”

• High stimulant exposure can increase glutamatergic activity, leading to excessive NMDA receptor activation, calcium influx, and downstream oxidative/enzymatic damage (“excitotoxicity”).

3) Mitochondrial dysfunction and energy failure

• Oxidative stress plus disrupted cellular ion balance can impair mitochondrial function, lowering ATP and increasing mitochondrial ROS—pushing neurons toward dysfunction and, in severe cases, cell death pathways.

4) Hyperthermia is a major amplifier

• For amphetamines, overheating isn’t just a side effect—it strongly increases risk of dopamine-terminal injury and broader neurodegeneration in animal models, likely by accelerating ROS production, protein misfolding, and membrane/ion-channel dysfunction.

Is there evidence for harm?

Despite these various neurotoxic mechanisms, the evidence for harm as a result of stimulants in treating ADHD is less obvious. A 1-year double-blind MRI study compared methylphenidate versus placebo in adults with ADHD to test concerns about potential neurotoxicity (brain volume loss). Across scans at baseline, 3 months, and 12 months, methylphenidate showed no detectable reductions in global or regional brain volume compared with placebo (Tebartz van Elst et al., 2016).

High-dose “binge” amphetamine or methamphetamine regimens in rodents produce persistent deficits in dopaminergic terminal markers in the dorsal striatum (the “reward centre” of the brain), with damage to terminals rather than substantia nigra cell bodies; oxidative stress from excess cytoplasmic dopamine is proposed as a key mechanism.

Comparable neurotoxicity is generally not seen in rodents with repeated lower (therapeutic-range) dosing, and methylphenidate high-dose studies are reported as negative for similar toxicity, possibly because methylphenidate blocks reuptake without disrupting vesicular dopamine storage.

However, a pivotal nonhuman primate study using an Adderall-like mixture for four weeks produced plasma levels comparable to human therapeutic exposure and showed 30–50% reductions across multiple striatal dopamine measures—effects resembling rodent neurotoxic outcomes (Ricaurte et al., 2005) This raises questions about exposure thresholds, individual vulnerability factors, aging-related susceptibility, and whether lifelong maintenance could interact with normal age-related dopamine decline.

The researchers found a number of alarming changes to the dopaminergic system:

• Clear dopaminergic deficits in the striatum after stopping amphetamine 2–4 weeks after cessation, with significant reductions in multiple dopaminergic terminal markers in striatum
• Caudate nucleus and putamen: 44–47% dopamine depletions
• Nucleus accumbens: ~30% depletion (smaller but still significant)
• A pronounced reduction in DAT binding and protein levels.

The key insight by the researchers is that these effects followed as a result of plasma amphetamine levels similar to those achieved in ADHD treatment. Patients on extended-release mixed amphetamine salts (highest dose examined 30 mg): total plasma amphetamine ~120 ng/ml. Dopaminergic marker losses were found in the baboon group with an amphetamine plasma concentration of ~168 ng/ml.

Conclusion

Overall, the evidence for harm caused by ADHD stimulant medications is mixed, being highly dependent on the dosing and test animal. Additionally, there appears to be a greater risk of harm associated with amphetamine, since it acts for as a dopamine releasing agent, whilst methylphenidate simply blocks reuptake,

High-dose stimulant exposure is neurotoxic in animal models, and a nonhuman primate study reported substantial reductions in striatal dopamine markers at plasma levels comparable to treated humans. Whether long-term therapeutic use in humans produces similar changes, but it raises concern that prolonged exposure—especially into late adulthood—could interact with normal age-related dopaminergic decline and merits longitudinal study.

References

Schiffer WK, Volkow ND, Fowler JS, Alexoff DL, Logan J, Dewey SL. Therapeutic doses of amphetamine or methylphenidate differentially increase synaptic and extracellular dopamine. Synapse. 2006 Mar 15;59(4):243-51. doi: 10.1002/syn.20235. PMID: 16385551.

van ElstLudger Tebartz, MaierSimon, KlöppelStefan, GrafErika, KilliusCarola, RumpMarthe, SobanskiEsther, EbertDieter, BergerMathias, WarnkeAndreas, MatthiesSwantje, PerlovEvgeniy, and PhilipsenAlexandra. 2016. The effect of methylphenidate intake on brain structure in adults with ADHD in a placebo-controlled randomized trial. Journal of Psychiatry and Neuroscience. 41(6): 422-430. https://doi.org/10.1503/jpn.150320

Ricaurte GA, Mechan AO, Yuan J, Hatzidimitriou G, Xie T, Mayne AH, McCann UD. Amphetamine treatment similar to that used in the treatment of adult attention-deficit/hyperactivity disorder damages dopaminergic nerve endings in the striatum of adult nonhuman primates. J Pharmacol Exp Ther. 2005 Oct;315(1):91-8. doi: 10.1124/jpet.105.087916. Epub 2005 Jul 13. PMID: 16014752.